Lymphoma

I'm using the lessons that cancer taught me to move forward in life.

The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted 16-0 in support of the agency granting approval to CT-P10, a biosimilar of Rituxan (rituximab), which is a drug used to treat non-Hodgkin lymphoma.

I shared some advice with another soon-to-be caregiver.

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.

September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:

From an inaugural gathering in 2009 that attracted approximately 700 people, the Life and Liberty event has grown in size each year, with more than 4,000 patients in attendance at last September’s celebration. Organizers said about 6,000 were there this year.

The Cutaneous Lymphoma Foundation connects patients with guidance and resources for this rare cancer.

Nicholas J. Vogelzang, M.D., FASCO, FACP, has seen cancer through a variety of lenses – from oncologist to patient as well as caregiver – giving him a different perspective than most.

Injectable forms of medication may benefit patients with blood cancers.

Team physician James Muntz diagnosed the blood cancer, and Hal then consulted with oncologists at The University of Texas MD Anderson Cancer Center in Houston.

The FDA has approved Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.

"One of the big challenges in lymphoma is that many immune cells are present right in the tumor, but somehow those immune cells are not actually killing the tumor cells," explained Stephen M. Ansell, M.D., Ph.D.

Moving on and focusing on your own future after cancer is an important step in the healing process.

How a cancer patient still made great memories during one of the most challenging times of his life.

How just another day at work triggered thoughts of having cancer as a child.

You are one person before the diagnosis comes, you are another person during the journey and you are different person when remission is gained. That is not to say that certain pieces of you don't remain, but I feel it nearly impossible to go through this journey unchanged.

Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.

Getting a job while having health issues can be a problem, but don't just take my word for it.

When dealing with cancer, it's important to know your limits and be OK with them, to focus on the good.

Focusing on the "and" instead of the rest

Having cancer can change the word "normal" forever.

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.

The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.

A look at how one cancer survivor has witnessed life-changing medical advancements over the years.

Four ways of helping cancer survivors deal with anxiety and depression.

There can be definite struggles for childhood cancer survivors, even many years later.

CURE spoke with the chief medical officer of the Leukemia & Lymphoma Society to hear what she thinks are important next steps in improving patient outcomes.

A new expert guideline for managing immunotherapy’s side effects has been released.

The FDA has granted an accelerated approval to Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy.